Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
codrituzumab (RG7686)
i
Other names:
RG7686, GC33, GC-33, RG-7686, RO 5137382, RO-5137382, RO5137382, GC 33, RG 7686
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Roche
Drug class:
GPC-3 inhibitor
Related drugs:
‹
BOS-342 (0)
CM350 (0)
ECT204 (0)
ERY974 (0)
NILK-2501 (0)
NILK-3801 (0)
NY-303 (0)
SAR444200 (0)
SENTI-301A (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
iCAR-ILC-N101 (0)
BOS-342 (0)
CM350 (0)
ECT204 (0)
ERY974 (0)
NILK-2501 (0)
NILK-3801 (0)
NY-303 (0)
SAR444200 (0)
SENTI-301A (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
iCAR-ILC-N101 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
GPC3 overexpression
Hepatocellular Cancer
GPC3 overexpression
Hepatocellular Cancer
atezolizumab + RG7686
Sensitive: C3 – Early Trials
atezolizumab + RG7686
Sensitive
:
C3
atezolizumab + RG7686
Sensitive: C3 – Early Trials
atezolizumab + RG7686
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login